- PLN124.77m
- PLN151.42m
- PLN15.76m
Brief: Mabion Resigns From Further Implementation Of MabionEGFR Research Project
Brief: Mabion Signs Statement Of Work With Novavax
Brief: Mabion Gets Additional Order For Production Of Cell Banks Under Deal With Novavax
Brief: Mabion Gets Permission For Carrying Out Clinical Research In Ukraine
Brief: Mabion Signs Deal With Swiss-Based Adolf Kühner
Brief: Mabion Q3 Net Loss Widens To 15.6 Mln Zlotys
Brief: Mabion Signs Quality Agreement With Novavax
Brief: Mabion Says Mylan Ireland Terminates Cooperation Deal
Brief: Mabion Gets Permission To Carry Out Bridge Clinical Trial Of MabionCD20 In Patients With Rheumatoid Arthritis In Belgium
Brief: Mabion Gets Permission To Run Bridging Clinical Trial Of MabionCD20 Drug in Georgia
Brief: Mabion Gets Permission For Briding Clinical Trial Of MabionCD20 Drug For Rheumatoid Arthritis Patients
Brief: Poland's Mabion CEO Says Term For Finding Strategic Investor May Extend Beyond 2021
Poland's Mabion surges on commercial production deal with Novavax
Brief: Mabion Signs $372 Commercial Scale Production Deal With Novavax
Brief: Mabion Q2 Net Loss Narrows To 2.5 Mln Zlotys
Brief: Mabion Gets Extension Of Permit For Carrying Out Activity In SEZ In Lodz
Brief: Mabion Has Adopted Joint Growth Strategy To Register Mabioncd20 On Both American And European Market
Brief: Mabion Gets Second Statement Of Work From Novavax
Poland - Factors to Watch June 16